Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diffuse Scleroderma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    66 result(s) found for: Diffuse Scleroderma. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2006-007091-15 Sponsor Protocol Number: CSTI571ENL18 Start Date*: 2007-09-03
    Sponsor Name:ErasmusMC
    Full Title: Glivec (imatinib mesylate) in systemic sclerosis, a pilot study
    Medical condition: systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039710 Scleroderma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003122-24 Sponsor Protocol Number: DISS01 Start Date*: 2008-04-09
    Sponsor Name:Daval International Limited
    Full Title: A Double-Blind Placebo-Controlled Pilot Study of the Safety and Tolerability of AIMSPRO in established Diffuse Cutaneous Systemic Sclerosis
    Medical condition: Diffuse Cutaneous Systemic Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012977 Diffuse systemic sclerosis LLT
    9.1 10036814 Progressive systemic sclerosis LLT
    9.1 10039710 Scleroderma LLT
    9.1 10012941 Diffuse scleroderma LLT
    9.1 10018124 Generalized scleroderma LLT
    9.1 10042954 Systemic sclerosis pulmonary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017869-27 Sponsor Protocol Number: TERSSC-001 incl. Amendment 1 Start Date*: 2010-09-23
    Sponsor Name:University Hospital Zurich
    Full Title: A dual-center, open-label Proof of Concept study to evaluate the efficacy of Terguride for the treatment of fibrosis in patients with systemic sclerosis.
    Medical condition: Diffuse scleroderma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012941 Diffuse scleroderma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007180-16 Sponsor Protocol Number: RITIS Start Date*: 2009-05-13
    Sponsor Name:LUMC
    Full Title: INFLUENCE OF B CELL DEPLETION BY MONOCLONAL ANTI-CD20 ANTIBODIES IN SYSTEMIC SCLERODERMA
    Medical condition: systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039710 Scleroderma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005116-21 Sponsor Protocol Number: CER-FT011-SSc01 Start Date*: 2021-09-27
    Sponsor Name:Certa Therapeutics Pty Ltd
    Full Title: A phase II, randomised, double blind, placebo-controlled study of the pharmacokinetics, pharmacodynamic effects, and safety, of oral FT011 in participants with diffuse systemic sclerosis
    Medical condition: diffuse systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10012977 Diffuse systemic sclerosis LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: PL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002015-38 Sponsor Protocol Number: ISD002-P144-07 Start Date*: 2007-08-23
    Sponsor Name:ISDIN
    Full Title: "ENSAYO CLÍNICO MULTICÉNTRICO, FASE II, ALEATORIZADO, DOBLE CIEGO, CONTROLADO INTRAINDIVIDUALMENTE CON PLACEBO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE P144 EN EL TRATAMIENTO TÓPICO DE LA FIBROSIS ...
    Medical condition: "FIBROSIS CUTÁNEA DE PACIENTES CON ESCLEROSIS SISTÉMICA" "SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS"
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039710 Scleroderma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Completed) GB (Completed) DE (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001617-27 Sponsor Protocol Number: IVA_01_337_HSSC_15_001 Start Date*: 2015-09-18
    Sponsor Name:Inventiva SAS
    Full Title: A randomized, double-blind, placebo-controlled, multicentre proof-of-concept trial of IVA337 in the treatment of diffuse cutaneous systemic sclerosis
    Medical condition: Systemic sclerosis (scleroderma) (SSc) is a chronic connective tissue disorder of unknown aetiology characterized by widespread microvascular damage and excessive deposition of collagen in the skin...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10012941 Diffuse scleroderma LLT
    18.0 100000004859 10074034 Generalised scleroderma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) GB (Completed) DE (Completed) NL (Completed) SI (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-005018-39 Sponsor Protocol Number: TDE-DU-201 Start Date*: 2009-03-05
    Sponsor Name:United Therapeutics Corporation
    Full Title: DISTOL-1:Digital Ischaemic Lesions in Scleroderma treated with Oral Treprostinil Diethanolamine: A randomized, double-blind, placebo controlled, multicenter study
    Medical condition: Systemic Sclerosis, scleroderma digital ulcers
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042953 Systemic sclerosis LLT
    9.1 10039710 Scleroderma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002651-25 Sponsor Protocol Number: R119220 Start Date*: 2017-07-11
    Sponsor Name:Research Governance and Integrity, University of Manchester
    Full Title: A Phase II Randomised Controlled Study of Oral Prednisolone in Early Diffuse Cutaneous Systemic Sclerosis
    Medical condition: Early diffuse cutaneous systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10012977 Diffuse systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-006978-15 Sponsor Protocol Number: TDE-DU-202 Start Date*: 2009-03-05
    Sponsor Name:United Therapeutics Corporation
    Full Title: DISTOL-EXT:Digital Ischaemic Lesions in Scleroderma treated with Oral Treprostinil Diethanolamine: An open-label multicenter extension study
    Medical condition: Systemic Sclerosis, scleroderma digital ulcers
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039710 Scleroderma PT
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10042953 Systemic sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003403-66 Sponsor Protocol Number: 1199.225 Start Date*: 2017-11-06
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD)
    Medical condition: Systemic Sclerosis associated Interstitial Lung Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10012977 Diffuse systemic sclerosis LLT
    21.0 100000004859 10036814 Progressive systemic sclerosis LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10042954 Systemic sclerosis pulmonary PT
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10025109 Lung involvement in systemic sclerosis LLT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) PT (Ongoing) GB (GB - no longer in EU/EEA) FR (Completed) DK (Completed) BE (Completed) AT (Completed) CZ (Completed) GR (Ongoing) SE (Completed) NO (Completed) FI (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-005322-68 Sponsor Protocol Number: farm 69j aj9 Start Date*: 2007-10-30
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
    Full Title: Low-dose oral imatinib in the treatment of scleroderma pulmonary involvement: a phase II pilot study
    Medical condition: Systemic Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10042953 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000230-33 Sponsor Protocol Number: HYDROXYSSc Start Date*: 2022-01-26
    Sponsor Name:UMBERTO I - POLICLINICO DI ROMA
    Full Title: A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADD-ON TRIAL EVALUATING EFFICACY AND SAFETY OF HYDROXYCHLOROQUINE IN EARLY SYSTEMIC SCLEROSIS (SSc)- HYDROXYSSc
    Medical condition: Systemic Sclerosis (SSc) is a rare and orphan disease (DPCM 12 gennaio 2017-GU SG n°65-S.O. n°15 - 18/03/2017), characterized by immunological, vascular and fibrotic abnormalities. The estimated in...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10042953 Systemic sclerosis LLT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003149-41 Sponsor Protocol Number: IgPro20_2001 Start Date*: 2019-07-16
    Sponsor Name:CSL Behring GmbH
    Full Title: A Multicenter, Randomized, Open-label, Crossover, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of IgPro20 (subcutaneous immunoglobulin, Hizentra®) and IgPro10 (intravenous immunoglob...
    Medical condition: Safety and Pharmacokinetics in subjects with diffuse cutaneous systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10012977 Diffuse systemic sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000701-61 Sponsor Protocol Number: BIRD-1 250705 Start Date*: 2005-11-29
    Sponsor Name:University College London
    Full Title: An open label trial of the dual specificity endothelin receptor antagonist bosentan in established scleroderma renal crisis
    Medical condition: Scleroderma renal crisis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000134-17 Sponsor Protocol Number: MT-7117-G02 Start Date*: 2020-12-23
    Sponsor Name:Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Diffuse Cutaneous Systemic Scle...
    Medical condition: Diffuse Cutaneous Systemic Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10012977 Diffuse systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) IT (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001353-16 Sponsor Protocol Number: BAY63-2521/16277 Start Date*: 2015-04-17
    Sponsor Name:Bayer AG
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
    Medical condition: diffuse cutaneous systemic sclerosis (dcSSc)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10012977 Diffuse systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) BE (Completed) ES (Completed) CZ (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001369-34 Sponsor Protocol Number: ACT12339 Start Date*: 2012-10-26
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: Double-blind, randomized, 8-week placebo-controlled and 16-week open label extension study investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients with...
    Medical condition: Systemic Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10028395 - Musculoskeletal and connective tissue disorders 10042953 Systemic sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001667-44 Sponsor Protocol Number: 11575705 Start Date*: 2011-06-28
    Sponsor Name:Active Biotech AB
    Full Title: An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with ABR-215757 (paquinimod)
    Medical condition: Systemic Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10042953 Systemic sclerosis PT
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10036814 Progressive systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019977-14 Sponsor Protocol Number: CILOS-RAY2010 Start Date*: 2010-11-04
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA
    Full Title: Efficacy of Cilostazol for the treatment of Raynaud’s Phenomenon in patients affected by Systemic Sclerosis
    Medical condition: Patients affected by Systemic Sclerosis with Raynaud’s Phenomenon
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042953 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 26 20:21:51 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA